Robert Lisicki Net Worth

The estimated Net Worth of Robert Lisicki is at least $7.08 Milhão dollars as of 3 August 2021. Mr. Lisicki owns over 17,500 units of Arena Pharmaceuticals Inc stock worth over $3,359,764 and over the last 5 years he sold ARNA stock worth over $458,765. In addition, he makes $3,260,860 as Executive Vice President and Chief Commercial Officer at Arena Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Lisicki ARNA stock SEC Form 4 insiders trading

Robert has made over 8 trades of the Arena Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 17,500 units of ARNA stock worth $716,625 on 3 August 2021.

The largest trade he's ever made was exercising 30,000 units of Arena Pharmaceuticals Inc stock on 4 August 2020 worth over $1,228,500. On average, Robert trades about 8,208 units every 55 days since 2019. As of 3 August 2021 he still owns at least 33,601 units of Arena Pharmaceuticals Inc stock.

You can see the complete history of Mr. Lisicki stock trades at the bottom of the page.

Robert Lisicki biography

Robert Lisicki serves as Executive Vice President and Chief Commercial Officer of the Company. Mr. Lisicki brings over 20 years of experience in biopharmaceutical management, sales and marketing to Arena. Mr. Lisicki most recently served as General Manager, Vice President Cardio-Metabolic and Inflammation at Regeneron Pharmaceuticals, Inc. Prior to joining Regeneron, he was Senior Vice President of Sales and Marketing and Chief Customer Officer at Daiichi Sankyo, Inc. Prior to Daiichi Sankyo, Mr. Lisicki held several management positions at Amgen Inc., including Vice President and General Manager, responsible for a 700+ person sales force in the U.S. His U.S. leadership experiences included such market shaping products Enbrel and Prolia. During his tenure he also covered several ex-U.S. regions, and worked as an International Franchise Lead running the development and international strategies and business plans across Amgen's portfolio including Nephrology, Cardiology, Bone and Oncology. Prior to joining Amgen, Mr. Lisicki held various sales and marketing positions at Johnson & Johnson Corporation. Mr. Lisicki holds a Bachelor of Science degree in Finance and Business Administration from the State University of New York at Albany.

What is the salary of Robert Lisicki?

As the Executive Vice President and Chief Commercial Officer of Arena Pharmaceuticals Inc, the total compensation of Robert Lisicki at Arena Pharmaceuticals Inc is $3,260,860. There are 2 executives at Arena Pharmaceuticals Inc getting paid more, with Amit Munshi having the highest compensation of $8,931,400.

How old is Robert Lisicki?

Robert Lisicki is 53, he's been the Executive Vice President and Chief Commercial Officer of Arena Pharmaceuticals Inc since 2018. There are 7 older and 5 younger executives at Arena Pharmaceuticals Inc. The oldest executive at Arena Pharmaceuticals Inc is Garry Neil, 67, who is the Independent Director.

What's Robert Lisicki's mailing address?

Robert's mailing address filed with the SEC is C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO, CA, 92121.

Insiders trading at Arena Pharmaceuticals Inc

Over the last 21 years, insiders at Arena Pharmaceuticals Inc have traded over $9,243,184 worth of Arena Pharmaceuticals Inc stock and bought 78,040 units worth $252,505 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Manmeet Singh Soni, eGarry Arthur Neil. On average, Arena Pharmaceuticals Inc executives and independent directors trade stock every 39 days with the average trade being worth of $3,133,387. The most recent stock trade was executed by Amit Munshi on 16 August 2021, trading 1,000 units of ARNA stock currently worth $48,190.

What does Arena Pharmaceuticals Inc do?

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas

Complete history of Mr. Lisicki stock trades at Arena Pharmaceuticals Inc

Arena Pharmaceuticals Inc executives and stock owners

Arena Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Amit Munshi,
  Director, President and Chief Executive Officer
• Vincent Aurentz,
  Executive Vice President and Chief Business Officer
• Robert Lisicki,
  Executive Vice President and Chief Commercial Officer
• Amit D. Munshi M.B.A.,
  Pres, CEO & Director
• Vincent E. Aurentz,
  Exec. VP & Chief Bus. Officer
• Dr. Christopher H. Cabell FACC, M.D., MHS,
  Advisor
• Laurie D. Stelzer,
  Exec. VP & CFO
• Joan Schmidt,
  Exec. VP, Gen. Counsel & Sec.
• Tina Nova,
  Independent Chairman of the Board
• Jennifer Jarrett,
  Independent Director
• Randall Woods,
  Independent Director
• Jayson Dallas,
  Independent Director
• Manmeet Soni,
  Independent Director
• Kieran Gallahue,
  Independent Director
• Oliver Fetzer,
  Independent Director
• Garry Neil,
  Independent Director
• Katharine Knobil,
  Director
• Joan Schmidt,
  Executive Vice President, General Counsel, Secretary
• Laurie Stelzer,
  Chief Financial Officer, Executive Vice President
• Patrick Malloy,
  VP of Investor Relations & Corp. Communications
• Megan E. Knight,
  Director of Investor Relations
• Dr. Lamine Mbow Ph.D.,
  Sr. VP & Chief Scientific Officer
• Dr. Douglas A. Bakan Ph.D.,
  Exec. VP of Technical Operations
• Harry F Jr Hixson,
  Director
• Maurice James Mezzino,
  SVP, Corporate Development
• Phillip M Schneider,
  Director
• Preston Klassen,
  EVP and CMO
• Steven W Spector,
  EVP, General Counsel & Sec
• Scott H Bice,
  Director
• Kevin Robert Lind,
  Executive VP and CFO
• Christine Anna White,
  Director
• Donald D Belcher,
  Director
• Nawal Ouzren,
  Director
• Frederick Frank,
  
• Mark N Lampert,
  Director
• Robert Hoffman,
  SVP, Finance and CFO
• Partners L P/Ilbiotechnolog...,
  
• James Laforce,
  Director
• Jennifer Kathleen Bielasz,
  VP, Accounting & Controller
• K A Ajit Simh,
  VP, Quality Systems
• Jack Lief,
  Chairman, President and CEO
• Craig Michael Audet,
  SVP, Opn & Head Glob Reg Afrs
• Duke K Bristow,
  Director
• Robert L Toms,
  Director
• Paul W Maffuid,
  VP, Pharmaceutical Development
• Joyce H Williams,
  VP, Drug Development
• Partners L P/Ilbvf Inc/Ilbi...,
  
• Nigel R A Beeley,
  VP, Chief Chemical Officer
• Joseph F Mooney,
  Chief Financial Officer
• Derek T Chalmers,
  Vice President, Research
• Louis J Scotti,
  VP, Marketing and Bus Dev
• Dominic P Behan,
  EVP & Chief Scientific Officer
• James Edeerfield Capital Lp...,
  
• Louis J Jr Lavigne,
  Director
• William R Jr Shanahan,
  SVP & Chief Medical Officer
• Christopher Cabell,
  EVP, Head of R&D, and CMO
• Steven J Schoch,
  Director
• Douglas J. Manion,
  EVP Research & Development